The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter
Abstract
This study evaluates the effectiveness and safety of intravenous diltiazem for the treatment of atrial fibrillation and atrial flutter. A double-blind, parallel, randomized, placebo-controlled protocol was used, and 6 large, urban hospitals, both university-affiliated and private, participated. The study involved 113 patients with atrial fibrillation or flutter, a ventricular rate greater than or equal to 120 beats/min and systolic blood pressure greater than or equal to 90 mm Hg without severe heart failure. The dose of intravenous diltiazem (or identical placebo) was 0.25 mg/kg/2 minutes followed 15 minutes later by 0.35 mg/kg/2 minutes if the first dose was tolerated but ineffective. If a patient did not respond, the code was broken and the patient was allowed to receive open-label diltiazem if placebo had been given. Of 56 patients, 42 (75%) randomized to receive diltiazem responded to 0.25 mg/kg and 10 of 14 responded to 0.35 mg/kg, for a total response rate of 52 of 56 patients (93%), whereas 7 of 57 patients (12%) responded to placebo (p less than 0.001). After the double-blind protocol, 49 of the 57 patients who received placebo were then given diltiazem; 47 of 49 responded, for an overall response rate of 99 of 105 patients (94%) with diltiazem. The median time from the start of drug infusion to the maximal decrease in heart rate was 4.3 minutes. Side effects occurred in 14 patients, 7 of whom had asymptomatic hypotension not requiring intervention. Thus, intravenous diltiazem was rapidly effective for slowing the ventricular response in most patients with atrial fibrillation or atrial flutter. Blood pressure decreased slightly. Side effects were mild.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is a particularly difficult goal in AFL and even the combination of AV node blocking drugs (digoxin, b blockers, calcium channel blockers) 135 -137 may fail, making cardioversion to sinus rhythm necessary.”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [137]
Citations
Cites
Chaffman, M. O., & Brogden, R. N. (1985) · Drugs · doi:10.2165/00003495-198529050-00001 · Cited by 374
Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm
Falk, R. H., Knowlton, A. A., Bernard, S. A., Gotlieb, N. E., & Battinelli, N. J. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-503 · Cited by 335
Waxman, H. L., Myerburg, R. J., Appel, R. A., & Sung, R. J. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-1-1 · Cited by 209
Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure
Walsh, R., Porter, C., Starling, M. R., & O’Rourke, R. A. (1984) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(84)80365-4 · Cited by 96
Electrophysiologic effects of diltiazem hydrochloride on supraventricular tachycardia
Rozanski, J. J., Zaman, L., & Castellanos, A. (1982) · The American Journal of Cardiology · doi:10.1016/s0002-9149(82)80021-0 · Cited by 82
Anderson, S., Blanski, L., Byrd, R. C., Das, G., Engler, R. L., Laddu, A. R., Lee, R., Rajfer, S. I., SCHROEDER, J. S., Steck, J. D., et al. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90551-x · Cited by 80
Betriu, A., CHAITMAN, B. R., Bourassa, M. G., Brévers, G., Scholl, J.-M., Bruneau, P., Gagné, P., & Chabot, M. (1983) · Circulation · doi:10.1161/01.cir.67.1.88 · Cited by 78
Steinberg, J. S., Katz, R. J., Bren, G. B., Buff, L. A., & Varghese, P. J. (1987) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(87)80396-0 · Cited by 66
Treatment of Atrial Arrhythmias
Haft, J. I. (1986) · Archives of Internal Medicine · doi:10.1001/archinte.1986.00360180067011 · Cited by 48
Stone, P. H. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90089-0 · Cited by 46
Morganroth, J., Horowitz, L. N., Anderson, J. L., & Turlapaty, P. (1985) · The American Journal of Cardiology · doi:10.1016/0002-9149(85)90914-2 · Cited by 41
Calcium entry blockers for systemic hypertension
Moser, M. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90186-x · Cited by 32
Hemodynamic effects of intravenous diltiazem with impaired left ventricular function
Materne, P. H., Legrand, V., Vandormael, M. G., Collignon, P., & KULBERTUS, H. E. (1984) · The American Journal of Cardiology · doi:10.1016/s0002-9149(84)80199-x · Cited by 31
Calcium antagonists for chronic stable angina pectoris
KRIKLER, D. M. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90088-9 · Cited by 28
Hung, J., Yeh, S., Lin, F., Fu, M., Lee, Y., & Wu, D. (1984) · The American Journal of Cardiology · doi:10.1016/s0002-9149(84)80076-4 · Cited by 27
Slow channel calcium antagonists in the treatment of supraventricular tachycardia
Talano, J. V., & Tommaso, C. L. (1982) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(82)90025-1 · Cited by 26
Theisen, K., Haufe, M., Peters, J., Theisen, F., & Jahrmärker, H. (1985) · The American Journal of Cardiology · doi:10.1016/0002-9149(85)90307-8 · Cited by 23
Kulick, D. L., McIntosh, N. A., Campese, V. M., Hsueh, W. A., Rahimtoola, S. H., Massry, S. G., & Elkayam, U. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90862-9 · Cited by 23
A review of medical therapy for coronary artery spasm.
Rl, F. (1987) · PubMed · Cited by 21
Comparison of calcium-entry blockers and diuretics in the treatment of hypertensive patients.
Sowers, J. R., & Pk, M. (1987) · PubMed · Cited by 14
Intravenous diltiazem for the treatment of supraventricular tachycardia
Sternbach, G. L., SCHROEDER, J. S., Eliastam, M., & Beier‐Scott, L. (1986) · Clinical Cardiology · doi:10.1002/clc.4960090403 · Cited by 13
Massie, B. M., Tubau, J. F., & Szlachcic, J. (1987) · PubMed · Cited by 10
Yeh, S., Fu, M., Lin, F., Lee, Y., Hung, J., & Wu, D. (1985) · CHEST Journal · doi:10.1378/chest.87.5.639 · Cited by 9
Cited by
Sorted by citations
Panchal, A. R., Bartos, J. A., Cabañas, J. G., Donnino, M. W., Drennan, I. R., Hirsch, K. G., Kudenchuk, P. J., Kurz, M. C., Lavonas, E. J., Morley, P. T., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000916 · Cited by 2,312
Topjian, A., Raymond, T. T., Atkins, D. L., Chan, M., Duff, J. P., Joyner, B. L., Lasa, J. J., Lavonas, E. J., Levy, A. R., Mahgoub, M., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000901 · Cited by 1,333
Brugada, J., Katritsis, D. G., Arbelo, E., Arribas, F., Bax, J. J., Blomström‐Lundqvist, C., Calkins, H. G., Corrado, D., Deftereos, S. G., Diller, G., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz467 · Cited by 1,312
Management of Patients With Atrial Fibrillation
Prystowsky, E. N., Benson, D. W., Fuster, V., Hart, R. G., Kay, G. N., Myerburg, R. J., Naccarelli, G. V., & Wyse, D. G. (1996) · Circulation · doi:10.1161/01.cir.93.6.1262 · Cited by 638
Page, R. L., Joglar, J. A., Caldwell, M. A., Calkins, H., Conti, J. B., Deal, B. J., Estes, N. A. M., Field, M. E., Goldberger, Z. D., Hammill, S. C., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000311 · Cited by 595
Metadata
- Authors
- Salerno, D. M., Dias, V. C., Kleiger, R. E., Tschida, V. H., Sung, R. J., Sami, M., & Giorgi, L. V.
- Affiliations
- San Francisco General Hospital (US)
- Corresponding author
- Salerno, David M.
- ORCID
- Salerno, David M.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 1989-05
- Volume
- 63
- Issue
- 15
- Pages
- 1046-1051
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W1998994470
- Cited by
- 152
- References
- 23
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 1 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 2 · 2013: 1 · 2012: 2
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- atrial fibrillation, atrial flutter, ventricular rate control, calcium channel blockers, antiarrhythmic efficacy, drug safety, hypotension, placebo response
- MeSH terms
- Aged, Atrial Fibrillation, Atrial Flutter, Blood Pressure, Diltiazem, Double-Blind Method, Female, Heart Rate, Humans, Injections, Intravenous, Male, Middle Aged, Random Allocation, Multicenter Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
